Inovio 3Q25 Review: EPS Miss, $25M Offering, And INO-3107 Progress

Core Insights - Inovio Pharmaceuticals reported disappointing earnings for Q3 2025, with a GAAP EPS loss of -$0.87, which was $0.45 below consensus estimates [1] - The company's cash position at the end of the quarter was $50.8 million, which may impact its operational capabilities moving forward [1] Financial Performance - The reported GAAP EPS loss of -$0.87 indicates significant underperformance compared to market expectations [1] - The stock price reacted negatively, initially sliding by 12% following the earnings announcement [1] Cash Position - Inovio ended the quarter with $50.8 million in cash and cash equivalents, which is crucial for funding ongoing operations and research [1]